Assertio Holdings, Inc.
https://www.assertiotx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Assertio Holdings, Inc.
ElevateBio Raises $401m To Fund Its Own And Partners’ Future Cell And Gene Therapy Needs
ElevateBio closed a series D venture capital round and revealed a potentially multibillion-dollar deal between its Life Edit subsidiary and Novo Nordisk as demand for its cell and gene therapy capabilities grow.
Assertio Targets Febrile Neutropenia Drug In Spectrum Buyout Deal
It remains unclear whether Rolvedon will achieve hoped-for sales milestones in a deal that Assertio said was part of a growth strategy emphasizing product and business acquisitions.
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Depomed, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice